{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:43:56Z","timestamp":1785141836703,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203888"],"award-info":[{"award-number":["82203888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82203888"],"award-info":[{"award-number":["82203888"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Dalian Medical Science Research Program","award":["2312016"],"award-info":[{"award-number":["2312016"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81972749"],"award-info":[{"award-number":["81972749"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Science and Technology Project of Liaoning","award":["2021JH2\/10300020"],"award-info":[{"award-number":["2021JH2\/10300020"]}]},{"name":"Liaoning Province talent plan project","award":["YXMJ-JC-04"],"award-info":[{"award-number":["YXMJ-JC-04"]}]},{"name":"Innovative Teams Project in Key Areas of Dalian","award":["2021RT01"],"award-info":[{"award-number":["2021RT01"]}]},{"name":"United Foundation for Dalian Institute of Chemical Physics. Chinese Academy of Sciences and the Second Hospital of Dalian Medical University","award":["DMU-2&DICP UN202301"],"award-info":[{"award-number":["DMU-2&DICP UN202301"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hereditas"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Regorafenib serves as a second-line treatment for patients with advanced hepatocellular carcinoma (HCC). Microsomal epoxide hydrolase 1 (EPHX1) is closely associated with tumorigenesis and drug resistance. However, the relationship between EPHX1 and regorafenib resistance, as well as the underlying mechanisms in HCC, remains unclear.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>To investigate the role and mechanisms of EPHX1 in mediating regorafenib resistance in HCC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We assessed the protein expression levels of EPHX1 in human HCC tissues and adjacent non-tumor tissues. Subsequently, we constructed HCC cell lines with EPHX1 overexpression and knockdown using lentiviral vectors and stimulated these cells with varying concentrations of regorafenib. We then measured cell proliferation and apoptosis using flow cytometry and Western blotting. Additionally, we established xenograft tumor models to explore the impact of EPHX1 on the in vivo efficacy of regorafenib. Furthermore, we employed digital gene expression sequencing (DGE-seq) to investigate and validate the specific molecular mechanisms by which EPHX1 mediates regorafenib resistance in HCC cells.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>We found that EPHX1 protein levels were significantly higher in HCC tissues compared to adjacent non-tumor tissues. EPHX1 inhibited the effects of regorafenib on cell proliferation and apoptosis. Consistently, the efficacy of regorafenib was enhanced in vivo following EPHX1 knockdown. Moreover, KEGG pathway enrichment analysis of DGE-seq data indicated that the JAK\/STAT signaling pathway is crucial for EPHX1-induced regorafenib resistance. Finally, EPHX1 suppressed regorafenib-induced inactivation of the JAK\/STAT signaling pathway and blocking this pathway with HY-N1447 alleviated EPHX1-induced regorafenib resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In summary, we conclude that EPHX1 enhances regorafenib resistance in HCC by activating the JAK\/STAT signaling pathway. Our findings suggest that EPHX1 is a key resistance-related gene, which has significant implications for the application of regorafenib in advanced HCC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41065-025-00517-1","type":"journal-article","created":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T18:00:49Z","timestamp":1753984849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["EPHX1 enhances drug resistance to regorafenib by activating the JAK\/STAT signaling pathway in hepatocellular carcinoma cell lines"],"prefix":"10.1186","volume":"162","author":[{"given":"Bin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuguang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BaiTong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gong","family":"Kai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binwen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,31]]},"reference":[{"issue":"3","key":"517_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"517_CR2","doi-asserted-by":"publisher","first-page":"16018","DOI":"10.1038\/nrdp.2016.18","volume":"2","author":"JM Llovet","year":"2016","unstructured":"Llovet JM, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018.","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"517_CR3","doi-asserted-by":"publisher","first-page":"e2435066","DOI":"10.1001\/jamanetworkopen.2024.35066","volume":"7","author":"M Yilma","year":"2024","unstructured":"Yilma M, et al. Survival outcomes among patients with hepatocellular carcinoma in a large integrated US health system. JAMA Netw Open. 2024;7(9):e2435066.","journal-title":"JAMA Netw Open"},{"key":"517_CR4","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.35371\/aoem.2021.33.e3","volume":"33","author":"JS Shin","year":"2021","unstructured":"Shin JS, et al. Relationship between job rotation and work-related low back pain: a cross-sectional study using data from the fifth Korean working conditions survey. Ann Occup Environ Med. 2021;33:e3.","journal-title":"Ann Occup Environ Med"},{"issue":"1","key":"517_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"517_CR6","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3350\/cmh.2022.0402","volume":"29","author":"D Xie","year":"2023","unstructured":"Xie D, et al. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Chinese perspective. Clin Mol Hepatol. 2023;29(2):206\u201316.","journal-title":"Clin Mol Hepatol"},{"issue":"8","key":"517_CR7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.dld.2017.04.022","volume":"49","author":"A Casadei Gardini","year":"2017","unstructured":"Casadei Gardini A, et al. Sorafenib and regorafenib in HBV- or HCV-positive hepatocellular carcinoma patients: analysis of RESORCE and SHARP trials. Dig Liver Dis. 2017;49(8):943\u20134.","journal-title":"Dig Liver Dis"},{"issue":"29","key":"517_CR8","doi-asserted-by":"publisher","first-page":"e21191","DOI":"10.1097\/MD.0000000000021191","volume":"99","author":"S Komiyama","year":"2020","unstructured":"Komiyama S, et al. Therapeutic effects of regorafenib after Sorafenib monotherapy with advanced hepatocellular carcinoma including Child-Pugh classification B: a retrospective observational study. Med (Baltim). 2020;99(29):e21191.","journal-title":"Med (Baltim)"},{"issue":"3","key":"517_CR9","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151\u201372.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"517_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF00040580","volume":"24","author":"S Krishnasamy","year":"1994","unstructured":"Krishnasamy S, Grant RA, Makaroff CA. Subunit 6 of the Fo-ATP synthase complex from cytoplasmic male-sterile radish: RNA editing and NH2-terminal protein sequencing. Plant Mol Biol. 1994;24(1):129\u201341.","journal-title":"Plant Mol Biol"},{"issue":"1\u20132","key":"517_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000015164","volume":"83","author":"JK Hartsfield Jr","year":"1998","unstructured":"Hartsfield JK Jr., et al. Assignment1 of microsomal epoxide hydrolase (EPHX1) to human chromosome 1q42.1 by in situ hybridization. Cytogenet Cell Genet. 1998;83(1\u20132):44\u20135.","journal-title":"Cytogenet Cell Genet"},{"issue":"1","key":"517_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.gene.2015.07.071","volume":"571","author":"R V\u00e1clav\u00edkov\u00e1","year":"2015","unstructured":"V\u00e1clav\u00edkov\u00e1 R, Hughes DJ, Sou\u010dek P. Microsomal epoxide hydrolase 1 (EPHX1): gene, structure, function, and role in human disease. Gene. 2015;571(1):1\u20138.","journal-title":"Gene"},{"issue":"17","key":"517_CR13","doi-asserted-by":"publisher","first-page":"5124","DOI":"10.3748\/wjg.v20.i17.5124","volume":"20","author":"QT Li","year":"2014","unstructured":"Li QT, et al. Association between esophageal cancer risk and EPHX1 polymorphisms: a meta-analysis. World J Gastroenterol. 2014;20(17):5124\u201330.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"517_CR14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/01.ede.0000187627.70026.23","volume":"17","author":"C Kiyohara","year":"2006","unstructured":"Kiyohara C, et al. EPHX1 polymorphisms and the risk of lung cancer: a huge review. Epidemiology. 2006;17(1):89\u201399.","journal-title":"Epidemiology"},{"issue":"4","key":"517_CR15","doi-asserted-by":"publisher","first-page":"e0123347","DOI":"10.1371\/journal.pone.0123347","volume":"10","author":"H Chen","year":"2015","unstructured":"Chen H, et al. Systematic review and Meta-Analysis of the relationship between EPHX1 polymorphisms and the risk of head and neck cancer. PLoS ONE. 2015;10(4):e0123347.","journal-title":"PLoS ONE"},{"issue":"8","key":"517_CR16","doi-asserted-by":"publisher","first-page":"e43821","DOI":"10.1371\/journal.pone.0043821","volume":"7","author":"F Liu","year":"2012","unstructured":"Liu F, et al. Systematic review and meta-analysis of the relationship between EPHX1 polymorphisms and colorectal cancer risk. PLoS ONE. 2012;7(8):e43821.","journal-title":"PLoS ONE"},{"issue":"1","key":"517_CR17","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1080\/21691401.2019.1622551","volume":"47","author":"Y Jin","year":"2019","unstructured":"Jin Y. Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis. Artif Cells Nanomed Biotechnol. 2019;47(1):2338\u201342.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"3","key":"517_CR18","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1002\/jcp.29206","volume":"235","author":"X Long","year":"2020","unstructured":"Long X, et al. LINC00205 modulates the expression of EPHX1 through the Inhibition of miR-184 in hepatocellular carcinoma as a CeRNA. J Cell Physiol. 2020;235(3):3013\u201321.","journal-title":"J Cell Physiol"},{"issue":"5","key":"517_CR19","doi-asserted-by":"publisher","first-page":"955","DOI":"10.32604\/or.2023.043922","volume":"32","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients. Oncol Res. 2024;32(5):955\u201363.","journal-title":"Oncol Res"},{"issue":"9","key":"517_CR20","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.1021\/acs.molpharmaceut.1c00462","volume":"18","author":"E El-Khateeb","year":"2021","unstructured":"El-Khateeb E, et al. Non-uniformity of changes in drug-Metabolizing enzymes and transporters in liver cirrhosis: implications for drug dosage adjustment. Mol Pharm. 2021;18(9):3563\u201377.","journal-title":"Mol Pharm"},{"issue":"4","key":"517_CR21","doi-asserted-by":"publisher","first-page":"e1900080","DOI":"10.1002\/prca.201900080","volume":"14","author":"R Sun","year":"2020","unstructured":"Sun R, et al. Proteomic analysis reveals that EPHX1 contributes to 5-Fluorouracil resistance in a human hepatocellular carcinoma cell line. Proteom Clin Appl. 2020;14(4):e1900080.","journal-title":"Proteom Clin Appl"},{"issue":"7782","key":"517_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","volume":"575","author":"N Vasan","year":"2019","unstructured":"Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299\u2013309.","journal-title":"Nature"},{"issue":"3","key":"517_CR23","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1093\/hmg\/3.3.421","volume":"3","author":"C Hassett","year":"1994","unstructured":"Hassett C, et al. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet. 1994;3(3):421\u20138.","journal-title":"Hum Mol Genet"},{"issue":"2","key":"517_CR24","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1134\/S0026893315020156","volume":"49","author":"D Wang","year":"2015","unstructured":"Wang D, et al. [EPHX1 Tyr113His polymorphism contributes to hepatocellular carcinoma risk: Evidfnce from a meta-analysis]. Mol Biol (Mosk). 2015;49(2):351\u201361.","journal-title":"Mol Biol (Mosk)"},{"issue":"1","key":"517_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s13277-013-1090-7","volume":"35","author":"CY Duan","year":"2014","unstructured":"Duan CY, et al. Lack of association of EPHX1 gene polymorphisms with risk of hepatocellular carcinoma: a meta-analysis. Tumour Biol. 2014;35(1):659\u201366.","journal-title":"Tumour Biol"},{"key":"517_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/1471-2407-14-282","volume":"14","author":"JY Chen","year":"2014","unstructured":"Chen JY, et al. Hepatitis B spliced protein (HBSP) promotes the carcinogenic effects of benzo [alpha] pyrene by interacting with microsomal epoxide hydrolase and enhancing its hydrolysis activity. BMC Cancer. 2014;14:282.","journal-title":"BMC Cancer"},{"key":"517_CR27","doi-asserted-by":"publisher","first-page":"145907","DOI":"10.1016\/j.gene.2021.145907","volume":"805","author":"ML Zhang","year":"2021","unstructured":"Zhang ML, et al. ABCB1 c.3435C\u2009>\u2009T and EPHX1 c.416A\u2009>\u2009G polymorphisms influence plasma carbamazepine concentration, metabolism, and pharmacoresistance in epileptic patients. Gene. 2021;805:145907.","journal-title":"Gene"},{"issue":"2","key":"517_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1006\/abbi.1996.9794","volume":"337","author":"C Hassett","year":"1997","unstructured":"Hassett C, et al. Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys. 1997;337(2):275\u201383.","journal-title":"Arch Biochem Biophys"},{"key":"517_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fonc.2018.00135","volume":"8","author":"L Mei","year":"2018","unstructured":"Mei L, et al. Advances and challenges on management of Gastrointestinal stromal tumors. Front Oncol. 2018;8:135.","journal-title":"Front Oncol"},{"key":"517_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ctrv.2017.10.011","volume":"62","author":"M R\u00f8ed Sk\u00e5rderud","year":"2018","unstructured":"R\u00f8ed Sk\u00e5rderud M, et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treat Rev. 2018;62:61\u201373.","journal-title":"Cancer Treat Rev"},{"key":"517_CR31","doi-asserted-by":"crossref","unstructured":"Saborido B et al. Diagnostic performance of contrast-enhanced US in small liver nodules not conclusively characterized after MRI in cirrhotic patients. Eur Radiol, 2025.","DOI":"10.1007\/s00330-025-11495-3"},{"key":"517_CR32","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fncel.2014.00187","volume":"8","author":"JT Mony","year":"2014","unstructured":"Mony JT, Khorooshi R, Owens T. Chemokine receptor expression by inflammatory T cells in EAE. Front Cell Neurosci. 2014;8:187.","journal-title":"Front Cell Neurosci"},{"issue":"50","key":"517_CR33","doi-asserted-by":"publisher","first-page":"43437","DOI":"10.1074\/jbc.M111.299313","volume":"286","author":"T Rauen","year":"2011","unstructured":"Rauen T, et al. cAMP-responsive element modulator (CREM)\u03b1 protein induces Interleukin 17A expression and mediates epigenetic alterations at the Interleukin-17A gene locus in patients with systemic lupus erythematosus. J Biol Chem. 2011;286(50):43437\u201346.","journal-title":"J Biol Chem"},{"issue":"5","key":"517_CR34","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1172\/JCI73411","volume":"124","author":"T Koga","year":"2014","unstructured":"Koga T, et al. CaMK4-dependent activation of akt\/mtor and CREM-\u03b1 underlies autoimmunity-associated Th17 imbalance. J Clin Invest. 2014;124(5):2234\u201345.","journal-title":"J Clin Invest"},{"issue":"5","key":"517_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nri1602","volume":"5","author":"TW Klein","year":"2005","unstructured":"Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol. 2005;5(5):400\u201311.","journal-title":"Nat Rev Immunol"},{"issue":"5985","key":"517_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/311433a0","volume":"311","author":"ME Greenberg","year":"1984","unstructured":"Greenberg ME, Ziff EB. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene. Nature. 1984;311(5985):433\u20138.","journal-title":"Nature"},{"issue":"2","key":"517_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/jem.20100466","volume":"208","author":"T Okazaki","year":"2011","unstructured":"Okazaki T, et al. PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395\u2013407.","journal-title":"J Exp Med"},{"key":"517_CR38","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0065-2776(10)05004-2","volume":"105","author":"K Fujio","year":"2010","unstructured":"Fujio K, Okamura T, Yamamoto K. The family of IL-10-secreting CD4\u2009+\u2009T cells. Adv Immunol. 2010;105:99\u2013130.","journal-title":"Adv Immunol"}],"container-title":["Hereditas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41065-025-00517-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41065-025-00517-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T10:12:59Z","timestamp":1757326379000},"score":1,"resource":{"primary":{"URL":"https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-025-00517-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,31]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["517"],"URL":"https:\/\/doi.org\/10.1186\/s41065-025-00517-1","relation":{},"ISSN":["1601-5223"],"issn-type":[{"value":"1601-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,31]]},"assertion":[{"value":"14 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All human tissue specimens were collected with written informed consent from participants in accordance with the Declaration of Helsinki. The studies involving human participants were reviewed and approved by the Ethics Committee of. The Second hospital of Dalian Medical University (Approval No. 2022166). For the use of human tissues, all patients provided explicit consent for participation of anonymized data derived from their specimens. All animal experiments were conducted in compliance with the ARRIVE guidelines and approved by the Institutional Animal Care and Use Committee (IACUC) of Wuhan Servicebio Technology Co., Ltd. (Approval No. 2024166).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"148"}}